

H3
concl'd

P. et al. (1988), Blood, 72:234-240), DEL (Barbey, S. et al. (1990), Int. J. Cancer, 45:546-553).

IN THE CLAIMS:

Please amend the claims as follows:

Amend claims 76, 83, 86 and 99 to read as follows:

76. (Four times amended) A monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said 8F4 polypeptide:

- A7
- a) is an inducible T cell costimulatory molecule;
 - b) occurs on two-signal-activated human T lymphocytes;
 - c) exhibits a molecular weight of about 55 to 60 kilodaltons as determined by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE); and
 - d) is a dimer of two peptide chains exhibiting molecular weights of about 27 kilodaltons and 29 kilodaltons, as measured by reducing SDS-PAGE,

wherein the human 8F4 polypeptide is recognized by the antibody deposited with the DSMZ and assigned accession no. DSM ACC2539;

wherein the monoclonal antibody, in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates proliferation of human T lymphocytes;

and wherein the monoclonal antibody inhibits costimulation of T lymphocytes by the human 8F4 polypeptide.

83. (Four times amended) A hybridoma that produces a monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said 8F4 polypeptide:

- A5
- a) is an inducible T cell costimulatory molecule;
 - b) occurs on two-signal-activated human T lymphocytes;
 - c) exhibits a molecular weight of about 55 to 60 kilodaltons as determined by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE); and
 - d) is a dimer of two peptide chains exhibiting molecular weights of about 27 kilodaltons and 29 kilodaltons, as measured by reducing SDS-PAGE,

432

NY2-1386431.1

wherein the human 8F4 polypeptide is recognized by the antibody deposited with the DSMZ and assigned accession no. DSM ACC2539;

H5
could

wherein the hybridoma produces a monoclonal antibody,

wherein the monoclonal antibody, in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates proliferation of human T lymphocytes;

and wherein the monoclonal antibody inhibits costimulation of T lymphocytes by the human 8F4 polypeptide.

86. (Four times amended) A pharmaceutical composition comprising a monoclonal antibody that recognizes a human 8F4 polypeptide, wherein said 8F4 polypeptide:

- H6
- a) is an inducible T cell costimulatory molecule;
 - b) occurs on two-signal-activated human T lymphocytes;
 - c) exhibits a molecular weight of about 55 to 60 kilodaltons as determined by non-reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE); and
 - d) is a dimer of two peptide chains exhibiting molecular weights of about 27 kilodaltons and 29 kilodaltons, as measured by reducing SDS-PAGE,

wherein the human 8F4 polypeptide is recognized by the antibody deposited with the DSMZ and assigned accession no. DSM ACC2539;

and wherein the pharmaceutical composition comprises a monoclonal antibody;

wherein the monoclonal antibody, in conjunction with anti-CD3 monoclonal antibody OKT3, costimulates proliferation of human T lymphocytes;

and wherein the monoclonal antibody inhibits costimulation of T lymphocytes by the human 8F4 polypeptide.

H7

99. (Amended) A hybridoma cell line deposited with the DSMZ and assigned accession no. DSM ACC2539.